Charles River Laboratories and Akron Bio have announced the integration of the latter’s closed system solutions (CSS) liquid cytokines into Charles River’s Cell Therapy Flex platform for process development.
The liquid cytokines are developed under current good manufacturing practices (CGMP).
Go deeper with GlobalData
The incorporation of Akron’s range of liquid cytokines enhances closed-system processing, optimising operations, reducing risk and strengthening process reliability.
Designed as an off-the-shelf solution for cell therapy process development, the platform integrates Akron’s CGMP liquid cytokines rHu IL-2, IL-7, IL-15 and IL-21, which are available in liquid formulations.
The formulations maintain protein stability at temperatures between 2°C and 8°C. The come in single-use, ready-to-use bags with weldable tubing, which reduces operator error risk and allows for quick, aseptic media formulation.
The integration further enables closed system processing – a significant step in automating platforms and protocols for cell therapies, including autologous CAR-T and TCR-T cell therapies.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataCharles River process development director Alex Sargent stated: “We’re excited to enhance our Cell Therapy Flex Platform offerings with closed system automation that scales manufacturing while working to improve the safety and efficacy of the drug product.
“With Akron Bio’s CSS [steady state plasma concentration] line, we can provide customers CGMP-ready critical raw materials already on file with the [US Food and Drugs Administration].”
Charles River has expanded its cell and gene therapy portfolio in recent years through acquisitions and expansions. These efforts aim to simplify complex supply chains and cater to increasing demand for viral vector, cell therapy services and plasmid DNA.
Akron Bio focuses on providing critical materials and services for advanced therapies.
In October 2024, FibroBiologics entered a master services agreement with Charles River to develop and manufacture cell-based therapies for chronic conditions.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
